PaxMedica 9/2/2026 Earnings Report

PaxMedica EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.88
• Beat/Miss: N/A
• One Year Ago EPS: N/A

PaxMedica Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

PaxMedica Announcement Details

• Date: 9/2/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

PaxMedica (NASDAQ:PXMD) is a clinical‐stage biopharmaceutical company headquartered in Burlingame, California. The company is dedicated to developing novel therapies for central nervous system disorders, with a particular emphasis on addressing unmet needs in autism spectrum disorders, mood disorders and related behavioral conditions. PaxMedica focuses on small-molecule candidates designed to modulate key neural pathways implicated in social and emotional regulation.

The company’s lead development program centers on arbaclofen, a proprietary formulation intended to improve social functioning in patients with autism spectrum disorders and associated behavioral challenges. PaxMedica has advanced preclinical and initial clinical work to assess the safety, tolerability and efficacy of this candidate. The company’s research activities leverage collaborations with academic centers and contract research organizations to support its translational pipeline and exploratory biomarker studies.

Founded in 2015, PaxMedica has assembled a management team with experience in neuroscience drug development and regulatory strategy. While the company’s primary operations are based in the United States, its clinical trial plans include potential international sites to facilitate patient enrollment. PaxMedica continues to build its pipeline through in-licensing and internal discovery efforts aimed at expanding therapeutic options for patients with challenging neurobehavioral conditions.